DSIP Dosing: What Protocols Exist and What Supports Them
DSIP is a synthetic nonapeptide studied since the 1970s under the generic name emideltide. It is not an FDA-approved drug, it is not an FDA-approved dietary ingredient, and it does not appear on the FDA's 503A bulk drug substances list that governs what compounding pharmacies may legally prepare (503A framework). Its nomination for that list was withdrawn by the nominators, and withdrawal is not the same as approval or safety clearance (FDA Category 2 bulk substances page, current as of April 22, 2026). In July 2026, the FDA's Pharmacy Compounding Advisory Committee took up emideltide again and voted against recommending it for the 503A list (meeting record). That is not regulatory momentum toward approval; it is the opposite. For a fuller status timeline, see DSIP's 2026 FDA status and the FDA Peptide Status Tracker.
Given all of that, the honest starting point for a "dosing" article is that there is no dose to recommend. What follows is an account of what has actually been tested, what is being reported informally, and why the gap between the two matters more for DSIP than for many other peptides.
What does the clinical trial evidence actually show about dosing?
The single controlled human trial on DSIP for sleep is a double-blind study in chronic insomnia patients (Neuropsychobiology, 1992). It is the only placebo-controlled human dosing evidence that exists for this indication. Because the full protocol details (route, exact dose, and administration schedule) sit behind the primary paper rather than in secondary summaries, anyone trying to translate that trial into a "real world" regimen needs to pull the original methods section rather than rely on secondhand paraphrase. What can be said without overreach: this was a supervised clinical research protocol, not a self-administered wellness regimen, and a positive signal in that setting does not license extrapolation to a different dose, route, or population.
A second human data point comes from a very different context: DSIP given intravenously as an adjunct during isoflurane anesthesia, where it altered EEG and heart rate variability measures in a monitored surgical setting (European Journal of Anaesthesiology, 2009). That is a perioperative, clinician-administered, single-exposure context. It tells us DSIP is pharmacologically active at some IV dose under anesthesia monitoring. It says nothing about a safe or effective subcutaneous dose for someone trying to sleep better at home.
Everything else in the human literature on DSIP is either older mechanistic work on ACTH suppression after IV injection (Psychoneuroendocrinology, 1989) or animal and formulation studies (rat aging models, hydrogel entrapment, hepatocyte stress response) that were never designed to generate a human dosing table.
Why does the short half-life make this harder, not easier?
Peptides generally clear quickly and cross the blood-brain barrier inefficiently compared with small molecules, which shapes how they need to be dosed and by what route (Peptides, 2015). DSIP is reported to have a short circulating half-life, and this is exactly the property that reported protocols use to justify multiple daily or multiple-nightly dosing schedules. That reasoning is plausible pharmacology, not validated practice. A short half-life is a real reason to expect that a single dose would not sustain any effect through the night, but no published human study has tested repeated-dose schedules against a single dose, compared routes, or established a minimum effective exposure. "Dose more often because it clears fast" is an inference, not a finding.
What are the protocols actually being reported, and what are they based on?
Community and vendor-reported protocols for DSIP describe subcutaneous injection, often nightly, sometimes cycled with rest periods. These regimens did not come from the 1992 trial's methodology, did not come from a pharmacokinetic study in humans, and are not the product of any clinician consensus body. They are practices that circulate informally, sometimes attributed loosely to "clinical experience," without a traceable primary source. Labeling them accurately matters: they are unvalidated compounding-and-self-administration practices operating in a product category that currently has no legal compounding pathway, not off-label prescribing of an approved drug and not a guideline-backed protocol.
A framework for evaluating any DSIP protocol you encounter
| Protocol claim you might see | What it is actually based on | Evidence tier |
|---|---|---|
| "DSIP improves deep sleep in insomnia" | One small double-blind trial in insomniac patients (1992) | Clinical trial evidence, single study, not replicated |
| "DSIP works best as an IV adjunct in surgical settings" | A monitored anesthesia study measuring EEG/HRV changes (2009) | Clinical trial evidence, different population and route than sleep self-use |
| "DSIP suppresses stress hormone response" | IV injection study measuring ACTH in humans (1989) | Mechanistic human data, not a dosing study |
| "DSIP dosed nightly because of its short half-life" | Reasoning from general peptide pharmacokinetics, not a DSIP-specific human PK trial | Plausible inference, unproven in humans |
| "Cycle DSIP with rest weeks" or specific mg protocols from forums/vendors | Anecdote, vendor marketing, or informal practice | Unverified site/community practice, no traceable clinical source |
| "DSIP protects aging tissue via antioxidant enzymes" | Rat studies on aging physiology and enzyme expression | Animal/mechanistic evidence only, not translatable to a human dose |
Use this table as a filter before adopting any specific number, frequency, or cycling schedule you read about: ask which row it belongs in, not just whether it sounds specific.
What is established, what is plausible, and what is not established
Established: DSIP has been studied in humans in at least two distinct controlled contexts, chronic insomnia and perioperative anesthesia adjunct, with measurable physiological effects reported in each. It has no FDA-approved indication, and its most recent regulatory review by an FDA advisory committee did not support even a compounding pathway.
Plausible but unproven: that DSIP's short half-life justifies more frequent dosing than a single nightly administration. That mechanistic effects seen in rodent aging studies would generalize to humans at any particular dose.
Not established: any specific human dose, route, frequency, or cycling schedule for sleep support outside a supervised research protocol. Long-term safety of repeated self-administration. Equivalence between anecdotal vendor protocols and the conditions under which the 1992 or 2009 trials were conducted.
Where this leaves someone considering DSIP for sleep
If the goal is evidence-backed sleep support, it is worth comparing what DSIP actually has behind it against alternatives with FDA-approved indications or stronger trial bases; see DSIP versus melatonin and DSIP versus prescription sleep aids. Anyone currently on a prescription sleep medication who is considering a switch should talk to a prescriber before stopping it; abrupt discontinuation of drugs like zolpidem or trazodone carries its own risks, covered in the zolpidem discontinuation protocol and trazodone discontinuation protocol. For the broader mechanism and safety picture on DSIP itself, see how DSIP is thought to work and DSIP side effects and safety.
Persistent insomnia, especially with daytime impairment, mood changes, or suspected sleep apnea, warrants clinical evaluation rather than self-directed peptide dosing. Anyone experiencing chest pain, severe shortness of breath, fainting, or signs of an allergic reaction after any injected substance needs urgent medical care, not a forum answer.